T. Rowe Price reports 586,990 shares (2.2%) in Tenax

T. Rowe Price Associates files an amended Schedule 13G reporting beneficial ownership of 586,990 shares of Tenax Therapeutics common stock.

Rhea-AI Filing Summary

T. Rowe Price Associates files an amended Schedule 13G reporting beneficial ownership of 586,990 shares of Tenax Therapeutics common stock. The filing states this represents 2.2% of the class and lists sole voting and sole dispositive power over those shares. The cover shows 05/31/2026 and the amendment is signed on 06/05/2026.

The filing is marked under the heading "Ownership of 5 Percent or Less of a Class," and includes a statement denying that the filer is the beneficial owner. No transaction price, acquisition date, or purchase method is disclosed in the excerpt.

Insights

Institutional Ownership Analyst

Large registered holder reports a 2.2% stake in Tenax Therapeutics.

The amendment lists 586,990 shares and 2.2% ownership with sole voting and dispositive power. The filing is categorized under "Ownership of 5 Percent or Less of a Class," indicating an SEC passive/beneficial ownership disclosure.

Timing: the cover shows 05/31/2026 and the signature is dated 06/05/2026. Cash‑flow treatment and acquisition method are not disclosed in the provided excerpt; subsequent filings would be required for transactional detail.

Compliance & Regulatory Specialist

The filing is an amended Schedule 13G/A with an ownership denial clause.

The document includes a declarative sentence: "Ownership of 5 percent or less of a class" and a statement expressly denying beneficial ownership. This language is common where an investment manager files on behalf of clients or in voting/dispositive power contexts.

Investors should note the filing's form and wording; it discloses holdings and powers but does not assert transactional intent or control actions.

Key Figures

Shares beneficially owned: 586,990 shares Percent of class: 2.2% Filing form: Schedule 13G/A +2 more

5 metrics

Shares beneficially owned 586,990 shares Item 4 ownership

Percent of class 2.2% Item 4 percent of class

Filing form Schedule 13G/A Amendment No. 3 header

CUSIP 88032L605 Cover page identifier

Date on cover 05/31/2026 Cover page date

Key Terms

Schedule 13G/A, beneficially owned, sole dispositive power, Ownership of 5 Percent or Less of a Class

4 terms

Schedule 13G/A regulatory

"Amendment No. 3 ) TENAX THERAPEUTICS INC COMMON STOCK"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned regulatory

"Item 4. | Amount beneficially owned: 586990"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 586990"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Ownership of 5 Percent or Less of a Class regulatory

"Item 5. | Ownership of 5 Percent or Less of a Class."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does T. Rowe Price hold in TENX?

T. Rowe Price reports ownership of 586,990 shares, equal to 2.2% of Tenax Therapeutics common stock. The Schedule 13G/A lists sole voting and sole dispositive power over those shares as provided in Item 4.

When is the ownership position dated in the TENX filing?

The cover shows the date 05/31/2026 and the amendment is signed on 06/05/2026. Those dates anchor the reported position and the signature of the filing representative, Ellen York.

Does the filing say T. Rowe Price is the beneficial owner of the shares?

The filing includes an express statement denying that T. Rowe Price is the beneficial owner. It still reports voting and dispositive powers for disclosure purposes under Item 4.

Does the Schedule 13G/A disclose how T. Rowe Price acquired the TENX shares?

No. The provided excerpt lists amount, percent, and powers but does not disclose acquisition dates, transaction prices, or methods of purchase in the visible text.

Is this filing material under the 5% ownership threshold?

Yes. The document is filed under the heading "Ownership of 5 Percent or Less of a Class," indicating the position is within that threshold while still requiring disclosure under Schedule 13G/A rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 11:41 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

TENAX THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

88032L605

(CUSIP Number)

05/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 586,990.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 586,990.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

586,990.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.2 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TENAX THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 101 GLEN LENNOX DRIVE, SUITE 300, CHAPEL HILL, NC, 27517
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 88032L605
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 586990
(b)	Percent of class: 2.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 586990
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 586990
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	06/05/2026